Gilead Sciences Inc (GILD)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

$98.39

Buy

$99.19

arrow-down$-3.05 (-3.01%)

Prices updated at 14 May 2025, 13:45 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
NASDAQ
arrow-up0.72%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Mr. Daniel P. O'Day
CEO
Mr. Daniel P. O'Day
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
17,600
Head office
333 Lakeside Drive
Foster City
United States
94404
mobile
+1 650 574-3000
letter
investor_relations@gilead.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Ms. Diane E. Wilfong
Interim Corporate Controller and Interim Chief Accounting Officer
-
Mr. Andrew D. Dickinson
Chief Financial Officer
1.08m
Mr. Anthony Welters
Lead Independent Director
0.16m
Dr. Jacqueline K. Barton, PhD
Independent Director
0.12m
Mr. Javier J. Rodriguez
Independent Director
0.10m
Dr. Ted W. Love, M.D.
Independent Director
0.08m
Mr. Harish Manwani
Independent Director
0.12m
Ms. Kelly Anne Kramer
Independent Director
0.14m
Mr. Daniel P. O'Day
Chairman of the Board and Chief Executive Officer
1.77m
Dr. Sandra J. Horning, M.D.
Independent Director
0.13m
Dr. Dietmar Berger, M.D.,PhD
Chief Medical Officer
-
Dr. Jeffrey A. Bluestone, PhD
Independent Director
0.10m
Ms. Johanna Mercier
Chief Commercial Officer
1.15m
Ms. Deborah H. Telman
Executive Vice President, Corporate Affairs and General Counsel
0.97m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Vanguard Group Inc117,470,825
BlackRock Inc116,104,572
Capital Research and Management Company107,391,073
State Street Corp60,381,755
FMR Inc58,542,842

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
16 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
29 Nov 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.